Lutein and Alzheimer's Disease Study

Phase 2

Terminated

• Conditions: Alzheimer's Disease
• Interventions: Dietary Supplement: lutein/zeaxanthin; Dietary Supplement: placebo

• Registration Number: NCT00596024
• Lead Sponsor: Oregon Health and Science University

Brief Summary

Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients.

The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2008-01-04
• Study First Submitted QC: 2008-01-04
• Study First Posted: 2008-01-16
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2019-08
• Last Update Submitted: 2019-08-08
• Last Update Posted: 2019-08-12

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

• Diagnosed with moderately severe Alzheimer's disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	lutein/zeaxanthin	Daily Lutein/zeaxanthin supplementation with a meal
2	placebo	-

Primary Outcome Measures

Name	Time	Method
oxidative damage markers	3 months

Trial Locations

Locations (1)

Oregon Health and Science University; 🇺🇸 Portland, Oregon, United States